Biliary-Pancreatic cancer
Conditions
Interventions
S-1 was administered orally after meals. The dosage of S-1 was 80mg/m2/day. S-1 is administred for 4 weeks followed by a 2-week rest. The administration of S-1 is continued for 1 year.
Sponsors
Osaka City University Graduate School of Medicine,Department of Hepato-Biliary-Pancreatic Surgery
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)pathologically diagnosed biliary or pancreatic cancer 2)pathologically curative resection 3)stage2,3,4 in Japanese Classification of Biliary or Pancreatic Carcinoma 4)no cancerous ascites and diatal metastasis 5)good oral intake 6)PS 0 or 1 (ECOG) 7)no previous chemotherapy or radiation in 3 years 8)administration of S-1 within 10 weeks after surgery 9)preserved organ function (bone marrow, liver,and kidney)
Exclusion criteria
Exclusion criteria: 1)previous treatment of S-1 2)recurrent case 3)fibroid lung or interstitial lung disease 4)active infectiou disease (excluding viral hepatitis) 5)sever complication 6)moderate ascites or pleural effusion 7)double cancer
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Feasibility | — |
Countries
Japan
Contacts
Public ContactHiroji Shinkawa
Osaka City University Department of Hepato-Biliary-Pancreatic Surgery
Outcome results
None listed